eFFECTOR Therapeutics, Inc. announced the publication of data highlighting the anti-tumor potential of zotatifin, the company?s clinical-stage inhibitor of eukaryotic translation initiation factor 4A (?eIF4A?), in the peer-reviewed journal Frontiers in Oncology. eIF4A is a catalytic component of the eIF4F complex, which regulates oncoprotein production at the level of mRNA translation. The published research showed that zotatifin downregulated the expression of certain receptor tyrosine kinases (?RTKs?), which are mutated and overexpressed in many cancers. The research also showed that rational combinations of zotatifin with the PI3K inhibitor alpelisib or the AKT inhibitor ipatasertib, both of which inhibit signaling downstream of RTKs, led to enhanced anti-tumor activity in vivo.